Prelude Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety. They are described as potentially useful for the treatment of cancer.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have identified pyrimidine-containing polycyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Cambridge Enterprise Ltd. has synthesized casein kinase II isoform α (CK2α) inhibitors reported to be useful for the treatment of cancer, viral infection, diabetes, ischemia, neurodegeneration, circadian rhythm disorders, vascular disorders and inflammatory disorders.
Gluetacs Therapeutics (Shanghai) Co. Ltd. has disclosed molecular glue degraders comprising cereblon (CRBN) ligands acting as DNA-binding protein Ikaros (IKZF1) or zinc finger protein Aiolos (IKZF3) degradation inducers reported to be useful for the treatment of cancer, autoimmune diseases, diabetes, infections, septic shock and more.
In what represents its first patenting, Halifax, Nova Scotia-based Hollo Medical Inc. seeks protection for its product that is designed for inhaler users who are frustrated with cumbersome valved holding chambers and desire something more compact and portable.
Nanjing Zhongrui Medicine Co. Ltd. has described protein phosphatase 2A (PP2A) activators reported to be useful for the treatment of Alzheimer’s disease.
Scientists at Nikang Therapeutics Inc. and Shanghai Blueray Biopharma Co. Ltd. have identified tetracyclic derivatives acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Scientists at Inventisbio Co. Ltd. and Inventisbio LLC have synthesized phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome).
RSS
